NCT05904080 2026-05-18Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerNational Cancer Institute (NCI)Phase 2 Recruiting50 enrolled